

# Monica A Konerman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6406206/publications.pdf>

Version: 2024-02-01

26  
papers

1,087  
citations

516215

16  
h-index

580395

25  
g-index

27  
all docs

27  
docs citations

27  
times ranked

2043  
citing authors

#	ARTICLE	IF	CITATIONS
1	Survey of Nonalcoholic Fatty Liver Disease Knowledge, Nutrition, and Physical Activity Patterns Among the General Public in Beijing, China. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3480-3488.	1.1	9
2	Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program. <i>Liver Transplantation</i> , 2019, 25, 369-379.	1.3	40
3	Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 296-307.	1.9	19
4	Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. <i>JAMA Oncology</i> , 2019, 5, 497.	3.4	67
5	Machine learning models to predict disease progression among veterans with hepatitis C virus. <i>PLoS ONE</i> , 2019, 14, e0208141.	1.1	59
6	Projected increase in obesity and nonalcoholic steatohepatitis-related liver transplantation waitlist additions in the United States. <i>Hepatology</i> , 2019, 70, 487-495.	3.6	96
7	Opioid and benzodiazepine prescription among patients with cirrhosis compared to other forms of chronic disease. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000271.	1.1	18
8	Pharmacotherapy for NASH: Current and emerging. <i>Journal of Hepatology</i> , 2018, 68, 362-375.	1.8	249
9	Long-term outcomes following completion of a structured nutrition and exercise lifestyle intervention program for patients with metabolic syndrome. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 753-759.	1.1	5
10	Editorial: being out of shape may impact more than your figure. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 582-583.	1.9	0
11	Hepatic encephalopathy impacts the predictive value of the Fried Frailty Index. <i>American Journal of Transplantation</i> , 2018, 18, 2566-2570.	2.6	45
12	Incidence of and Risk Assessment for Adverse Cardiovascular Outcomes After Liver Transplantation. <i>Transplantation</i> , 2017, 101, 1645-1657.	0.5	82
13	Overview of Clinical Treatment Trials for NASH. <i>Current Hepatology Reports</i> , 2017, 16, 366-373.	0.4	0
14	Impact of an electronic health record alert in primary care on increasing hepatitis c screening and curative treatment for baby boomers. <i>Hepatology</i> , 2017, 66, 1805-1813.	3.6	92
15	Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C. <i>PLoS ONE</i> , 2017, 12, e0187344.	1.1	26
16	Endoscopic Ultrasound as a Diagnostic Tool in a Case of Obscure Hemobilia. <i>ACG Case Reports Journal</i> , 2016, 3, e170.	0.2	7
17	Hepatitis C Treatment and Barriers to Eradication. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e193.	1.3	57
18	Interferon Treatment for Hepatitis B. <i>Clinics in Liver Disease</i> , 2016, 20, 645-665.	1.0	81

#	ARTICLE	IF	CITATIONS
19	Editorial: the burden and aetiology of liver cirrhosis, and the risk of death. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 202-203.	1.9	2
20	Dynamic prediction of risk of liver-related outcomes in chronic hepatitis C using routinely collected data. <i>Journal of Viral Hepatitis</i> , 2016, 23, 455-463.	1.0	7
21	Primary Care Physician Perspectives on Hepatitis C Management in the Era of Direct-Acting Antiviral Therapy. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3460-3468.	1.1	34
22	Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data. <i>Hepatology</i> , 2015, 61, 1832-1841.	3.6	54
23	Is It More Cost-effective for Patients With Chronic Hepatitis B to Have a Trial of Interferon Before Considering Nucleos(t)ide Analogue Therapy?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 386-389.	2.4	6
24	Diagnostic Challenges of Hepatitis C. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2536.	3.8	5
25	Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring – predictors and predictive models of disease progression. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 863-879.	1.9	21
26	Randomized, controlled pilot study comparing large-volume paracentesis using wall suction and traditional glass vacuum bottle methods. <i>Therapeutic Advances in Gastroenterology</i> , 2014, 7, 184-192.	1.4	4